Imagine a joint like a rusty hinge that hurts to move. Instead of just oiling it with temporary fixes, this project creates a smart gel that acts like a targeted delivery service, sending tiny genetic 'off-switches' to stop pain and inflammation at the source. It also uses a computer program to help doctors pick the exact right treatment for each person's specific joint damage.
Current osteoarthritis treatments are often costly, inefficient, and only manage symptoms without curing the disease. There is a massive unmet need for therapies that can stop or reverse joint degeneration for over 500 million people.
A 1st Generation therapeutic combining siRNA (targeting IL1B and NGF), self-healing hyaluronic acid hydrogels, and slow-release diclofenac systems. Additionally, a machine-learning tool for personalized diagnosis was developed.
If you are a biotech drug developer dealing with the lack of cures for knee osteoarthritis — this project developed a pipeline of siRNA-based therapies that block inflammation and pain signals. This allows for the creation of treatments that could potentially reverse the disease rather than just managing symptoms.
If you are a manufacturer dealing with low-efficacy hyaluronic acid injections — this project developed a self-healing modified hydrogel. This material can be loaded with nanocarriers to deliver drugs slowly and effectively into the joint.
If you are an AI company dealing with the complexity of personalized joint treatment — this project developed a decision-making tool based on machine learning. It uses patient data to offer a personalized therapy path for osteoarthritis.
Based on available project data, specific pricing is not mentioned, but the project objective is to create a 'cost effective' combined advanced therapy to replace current costly and inefficient options.
The project has produced 1st Generation therapeutics and prototypes of vectors and hydrogels. However, based on available project data, full industrial scale-up details are not yet provided.
Based on available project data, specific patents are not listed, but the project follows Quality-by-Design approaches to maximize the transition into clinics.
The team is performing an exhaustive analysis of regulatory requirements to ensure the siRNA and hydrogel products can successfully move into clinical settings.
The project runs from 2022-05-01 to 2026-10-31, suggesting that clinical validation and final product refinement are ongoing through 2026.
The consortium is well-balanced for translation, consisting of 13 partners across 9 countries. With a 23% industry ratio (3 industrial partners, including 3 SMEs), there is a clear bridge between the 5 universities and 5 research centers. This structure suggests a strong focus on moving the RNA-based therapy from lab discovery to a viable medical product.
Contact FUNDACION CIDETEC in Spain for licensing and partnership inquiries.
Contact us to explore licensing opportunities for the 1st Generation SINPAIN therapeutics.
